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The introduction of tacrolimus has shown de-
creased rates of acute and steroid-resistant rejec-
tion after liver transplantation (LTx). The aim of 
the present study is to examine the long-term 
efficacy and safety of tacrolimus in primary liver 
transplant recipients. The first 121 consecutive 
adults (aged >16 years) who underwent primary 
LTx at a single center from August 1989 to Febru-
ary 1990 were followed up until August 1997. The 
mean follow-up was 93.2 ± 1.2 months (range, 
90.5 to 96.5 months). Patient survival, graft sur-
vival, rate of rejection, and adverse events were 
examined. The actual 7-year patient survival rate 
was 67.8%, and the graft survival rate was 63.6%. 
Infections, recurrence of disease, de novo malig-
nancies, and cardiovascular events constituted 
the main causes of graft loss and death in the long 
term. Graft loss related to acute or chronic rejec-
tion was rare. The rate of acute rejection beyond 2 
years was approximately 3% per year, and most 
rejections were steroid responsive. Approxi-
T acrolimus is a macrolide isolated from the soil fungus, Tsukubaensis. It is a potent immuno-
suppressive agent. The first clinical trial with 
tacrolimus began at our institution in March 1989, 
initially as rescue treatment for failing liver allo-
grafts under cyclosporine (CSA).1.3 Subsequently, 
its use was evaluated by Todo et al45 in primary 
liver transplantation (LTx). Reduced episodes of 
acute rejection were shown by 1990.0.7 Three large 
prospective randomized trials were conducted: the 
University of Pittsburgh,K the United States multi-
center, and European multicenter trials comparing 
tacrolimus with CsA. 9·1 t Significantly lower rates of 
rejection and steroid-resistant rejection were shown 
in all three trials. little is known, however, about 
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mately 70% of the patients received only tacra-
limus after 1 year. Four patients developed end-
stage renal disease, and 2 patients underwent 
kidney transplantation. Hyperkalemia and hyper-
tension were observed in one third of the patients. 
New-onset insulin-clependent diabetes mellitus 
was observed in 9% and 13% of the patients at the 
1-year and 7-year follow-up, respectively. Seven 
patients developed de novo malignancies, includ-
ing two skin malignancies. Six patients developed 
posttransplantation Iymphoproliferative disorder 
during the entire follow-up period. Actual patient 
and graft survival at 7 years was excellent, and 
few adverse events developed after the first year. 
Graft loss from acute or chronic rejection was 
rare under tacrolimus, and approximately 70% of 
the patients were steroid free on tacrolimus mona-
therapy after the first year after LTx. 
Copyright © 1999 by the American Association for 
the Study of Liver Diseases 
the long-term impact of tacrolimus in liver trans-
plant recipients. 
The present study reports the long-term results 
of tacrolimus-based immunosuppression in pri-
mary adult liver transplant recipients with more 
than 90 months of follow-up. It examines patient 
survival, graft survival, causes of death, causes of 
retransplantation, rates of rejection, treatment of 
rejection, baseline immunosuppression, and ad-
verse events. 
Patients and Methods 
This study includes the first 121 consecutive adults 
(aged> 16 years) who underwent primary LTx under 
tacrolimus-based immunosuppression between August 
1989 and February \990, There were 68 men and 53 
women with a mean age of 46.3 ::t 12.3 years. Ninety-
eight patients (81%) were hospllal bound at the time of 
LTx, All patients were followed up until August 31, 
1997. The mean follow-up was 93.2 ::t 1.2 months 
(range, 90.5 to 96.5 months), The indications for LTx are 
listed in Table 1. Our immunosuppressive protocol has 
been previously described."'>! The doses of tacrolimus 
used in this initial trial were three lO fiye limes greater 
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Table 1. Indications for Adult Liver Transplantation 
Indications No. % 
Alcoholic cirrhosis 29 24 
Hepatitis non-A non-B 19 16 
Hepatitis B 15 12 
Hepatitis C 12 10 
Primary biliary cirrhosis 12 10 
Cryptogenic cirrhosis 10 8 
Sclerosing cholangitis 10 8 
Miscellaneous 14 12 
Primary liver malignancy 3 
Toxic hepatitis 2 
Crigler-Najjar disease 1 
Biliary atresia 1 
Secondary biliary cirrhosis 1 
Budd-Chiari syndrome 1 
Caroli's disease 1 
Hemochromatosis 1 
Trauma 1 
Alagille syndrome 1 
Wilson's disease 1 
Total 121 100 
than the current dosages.S.11 All palients in this popula-
tion received tacrolimus, 0.15 mglkg intravenously, on 
the first day and then 0.075 mglkg lwice daily over 2 to 4 
hours as a constant infusion."'? All intravenous tacro-
limus has been administered as a conunuous infusion at 
our institution since February 1991. Oral doses were 
administered when a patient could tolerate oral fluids. 
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Adjustments in tacrolimus dosage were made on an 
individual basis, depending on the state of renal and liver 
function and the presence of rejection, infection, and 
neurotoxicity. The first 53 patients received 1 g of 
methylprednisone after perfusion of the liver, followed 
by a total of 600 mg of methylprednisone tapered over 
the next 5 postoperative days, starting with 200 mg on 
the first day (divided into four doses) and reduced to 40 
mgld over the next 4 days. The remaining 68 patients 
received only 20 mg of methylprednisone.6 .? 
The diagnosis of rejection was determined by an 
increase in serum bilirubin and hepatic enzyme levels in 
the absence of any technical complication, ischemic 
injury, or development of hepatitis (hepatitis S, hepatitis 
C, or cytomegalovirus). All patients also underwent 
protocol liver biopsies between postoperative days 10 
and 14.6•8.11 Episodes ofacute rejection were treated with 
1 g of hydrocortisone or 1 g of methylprednisone with or 
without 600 mg of methylprednisone tapered over the 
next 5 days. Steroid-resistent rejections were treated with 
OKT3, 10 mL, over 5 to 7 days. 
Results 
Patient and graft survival rates are shown in Figure 
1. Mortality was more prominent in the first year 
after LTx. Thereafter, it averaged 3% every year, 
with an actual patient survival rate of 67.8% and 
graft survival rate of 63.6% at 7 years. Causes of 
death are shown in Table 2. Infection was the most 
common cause of death, particularly during the 
first year. Thereafter, recurrence of disease, de novo 
malignancies, and cardiovascular events consti-
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Months post-transplant 
Figure 1. Actual patient and graft survival rates over time. 
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Months Posttransplantation 
Causes 0-:53 >3-:512 >12-",24 >24-:536 >36-:548 >48-:560 >60-:572 >72-:584 >84-",96· Total 
Infection 5 4 2 1 2 2 1 17 
Sepsis 5 2 1 1 9 
Fungal 3 1 1 5 
CMV 1 1 2 
Protozoal-cryptococcal 1 1 
Recurrent disease 1 1 2 1 1 1 7 
HBV 1 2 1 4 
HCV 1 1 2 
HCC 1 1 
Cardiovascular 1 1 2 4 
Cerebrovascular 2 1 3 
De novo malignancy 1 1 1 3 
Noncompliance 1 1 2 
Pancreatitis 1 1 2 
Uremia 1 1 
Retransplantation bleeding 1 1 
Unknownt 1 1 2 
Total B 7 6 3 4 3 3 5 3 42 
Abbreviations: CMV, cytomegalovirus; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma. 
'Current follow-up_ 
tSudden unexpected deeth at home. 
tuted important causes of death. In 2 patients, the 
cause of death could not be established; both died 
suddenly and unexpectedly at home with normal 
liver function_ 
Causes for Retransplantatlon 
Twenty patients lost their first graft and underwent 
a second transplantation. Seven patients required a 
third transplant, and 2 patients needed a fourth 
transplant. Primary nonfunction, hepatic artery 
thrombosis, and recurrence of disease were the 
most common indications for retransplantation 
(Table 3). 
Rate of Rejection 
The highest incidence of rejection occurred in the 
first 3 months after LTx. The rates of rejection, as 
listed in Table 4, progreSSively decreased over time 
from 45% in the first 3 months to 18% from 3 to 12 
months, 13% in the second year, and 2% per year 
after the second year. 
Fifty-four episodes of rejection requiring treat-
ment occurred between 3 and 84 months after LTx 
in 52 patients. These episodes were controlled with 
I-g boluses of methylprednisone in 42 instances 
(78%) and I-g boluses of hydrocortisone in 12 
instances (22%). One patient also received OKT3. 
Two primary grafts were lost because of acute and 
chronic rejection. Three second transplants were 
lost because of acute rejection in 1 patient and 
chronic rejection in 2 patients during the entire 
study period. 
Liver Function 
liver function test results in all surviving patients 
were stable. The mean serum bilirubin, alanine 
.. --
, ,.' . ·iii$:t~f~·1 
lable 3. Causes of RetransPI~~~~~X, 
No. of CUes 
First Second Third 
Causes Graft Graft Graft 
Primary nonfunction 6 2 0 
Hepatic artery thrombosis 4 0 2 
Biliary necrosis 2 0 0 
Acute rejection 1 1 0 
, 
Chronic rejection 1 2 0 
Recurrence of disease 5 1 0 
HCV 3 
PSC 2 1 
Portal vein stenosis 1 0 0 
Lymphoproliferative disorder 0 1 0 
Total 20 7 2 
Abbreviations: HeV, hepatitiS C virus; PSC, primary 
sclerosing cholangitis. 
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Table 4. Complete Results of the Study 
Months Post-liver Transplantation 
12 24 36 48 60 72 84 
Survival 
Patients (%) 87.6 82.6 80.2 76.9 74.4 71.9 67.8 
Grafts (%) 82.6 78.5 76.9 72.7 68.6 66.9 63.6 
Patients at fisk (no.) 106 100 97 93 90 87 82 
Rejection no. (%) 22 (18)' 16 (13) 4 (3) 4 (3) 2 (2) 3(3) 1 (1) 
Immunosuppression 
Tacrolimus dose (mglkgld) 0.15 ::: 0.09 0.12::: 0.06 0.09::: 0.06 0.08::: 0.06 0.08::: 0.06 0.06::: 0.03 0.04::: 0.03 
Tacrolimus level (nglmL) 0.76::: 0.5 0.73::: 0.54 0.73::: 0.39 0.53::: 0.3 8.8::: 5.9t 6.4::: 7.3t 7.5::: 4.5t 
Prednisone dose (mgld) 
0(%) 72 70 64 70 62 70 74 
1-5(%) 13 17 23 19 24 21 22 
6-10 (%) 11 9 10 8 9 6 4 
11-20 (%) 4 4 3 3 6 4 1 
Azathioprine (mgld) 
25-50 (no.) 0 6 5 4 9 9 6 
75 (no.) 0 1 1 1 3 1 1 
100 (no.) 0 1 3 3 3 2 1 
Liver function 
Total bilirubin (mgldL) 0.7::,: 0.7 0.7::: 0.3 0.7::: 0.4 0.7::: 0.3 0.8::: 0.3 0.7 ::: 0.3 0.8::: 0.9 
AST(U/L) 36::: 28 56::: 81 46::: 46 36:!: 21 38::: 24 36::: 31 38::: 22 
ALT(UlL) 37::: 28 52::: 94 45::: 45 38::: 30 41 ::: 31 46::: 34 42::: 29 
GGT(UlL) 93::: 144 154::: 302 122::: 225 96::: 157 113::: 152 87::: 142 116::: 162 
Alkaline phosphatase (UIL) 114::: 58 113::: 85 118::: 68 117 ::: 72 113::: 54 117 ::: 106 119::: 94 
Renal function 
BUN (mgldL); 26::: 11 27::: 11 26::: 11 25::: 5 25::: 11 27::: 17 24::: 10 
Creatinine (mgldL)* 1.6::: 0.5 1.6::: 0.5 1.7::: 0.5 1.6::: 0.4 1.6::: 0.5 1.7::: 0.7 1.5::: 0.5 
<1.5(%) 49 43 42 43 55 44 58 
2:1.5-52.0 (%) 35 36 42 43 25 36 31 
2:2.0-52.5 (%) 9 18 11 10 14 11 6 
2:2.5 (%) 7 3 4 3 6 9 6 
Kidney Ix (Iotal) 2 
Dialysis (current) 2 
Cholesterol (mgldL) 173::: 43 180::: 48 181 :!: 47 181 ::: 46 182::: 50 178::: 50 196::: 61 
Hyperkalemia (K > 5.0 mEq/L) 54 56 50 43 40 33 30 
Hypertension 23 24 29 23 32 31 31 
Insulin-dependent diabetes mellilus 9 15 18 15 10 13 11 
De novo malignancy (total) 7 
Skin cancer (total) 2 
Other malignancy (total) 5 
PTLD (total) 6 
NOTE. Bilirubin. 1 mgldL = 17 ~moIlL. SI units: BUN. 1 mgldL = 0.357 ~mol/L. SI units: creatinine. 1 mgldL = 88.4 ~moVL. Sl Units. 
Abbreviations: ALT. alanine aminotransferase; AST. aspartate aminotransferase: BUN. blood urea nitrogen; GGT. gamma-glutamyl 
transferase. 
'From 3- to 12-month interval. 
tWhole-blood level (level <5 calculated as 5). 
:j:Patients on dialysis censured from calculation. 
aminotransferase. aspartate aminotransferase. gama 
glutamyl transferase (GGT). and alkaline phos-
phate levels at each year are shown In Table 4. 
Maintenance of Immunosuppression 
Tacrolimus. The mean tacrolimus dose was less 
each year and decreased from O.lS mg/kgld during 
the first year to 0.04 mglkgld at vear 7. Similarly. 
mean plasma tacrolimus trough concentrations 
were 0.76 nglmL at 1 year and 0.5 nglmL at 4 years. 
Since August 1994, we measured trough whole-
blood tacrolimus concentrations, and mean concen-
trations were 8.8, 6.4, and 6.2 ng/mL at S, 6, and 7 
years, respectively (Table 4). 
Cyclosporine. One patient, because of severe head-
aches, was switched to CsA in the first year and has 
remained on CsA. None of the patients received 
CsA and tacrolimus sImultaneously. 
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Prednisone. Approximately 70% of the patients 
were maintained without prednisone. For those 
who received prednisone at 1 year, the dose of 
prednisone decreased in subsequent years. Fifteen 
percent of the patients were receiving greater than 
5 mgld of prednisone at 1 year, and this declined to 
5% at 7 years (Table 4). 
Azathioprine. Azathioprine was not used in the 
first year after LTx. It was used after the first year to 
improve renal function by reducing the dose of 
tacrolimus. The number of patients receiving aza-
thioprine varied from 8 patients during the second 
year to 15 patients in the seventh year. At most 
times, more than two thirds of the patients were 
receiving 50 mgld or less of azathioprine. None of 
the patients received more azathioprine than 100 
mgld at any time (Table 4). 
Adverse Events 
NephrotOxicity. Nephrotoxicity was the most com-
mon complication of tacrolimus, as previously 
described. However, there was little change in the 
mean serum creatinine and blood urea nitrogen 
levels over 7 years when dialYSis-dependent pa-
tients were excluded (Table 4). More than 80% of 
the patients had serum creatinine levels of 2.0 
mgldL or less. Two patients, however, underwent 
kidney transplantatIOn for end-stage kidney dis-
ease attributable to tacrolimus toxicity at 12 and 28 
months after LTx. Two other patients are currently 
undergOing hemodialysis. 
Neurotoxicity. In this population, the initial doses 
of tacrolimus were three to five times greater than 
those currently used. Transient confusional state 
and tremor were common; however, these compli-
cations were not properly documented. Major 
neurological complications have been reponed on 
a larger population from our institution. 12 The 
majority of neurotoxicity occurred in the immedi-
ate postoperative penod and was dose dependent. 
Hyperkalemia. As shown in Table 4, more than 
50% of the patients in the first 3 years had 
hyperkalemia (K+ > 5.0 mEqlL) requiring treat-
ment. ApproXimately one third of the patients had 
hyperkalemia by 7 years (Table 4). In all cases, 
hyperkalemIa was readily controlled with fludrocor-
tisone. 
Hypertension. Thirty-one percent of the panents 
developed new-onset hypertenSion. defined as the 
need for any hypertenSion medication to control 
blood pressure. Patients who received diuretics 
alone were excluded because these were admmis-
tered more often for fluid retention with renal 
impairment at our center. In more than 75% of the 
patients, hypertenSion was controlled with a small 
dose of a Single antihypertenSive agent, usually a 
calcium channel blocker (Table 4). 
New-onset insulin-dependent diabetes mellitus. Nine 
percent of the patients at 1 year and 13% of the 
patients at 7 years were on insulin therapy. None of 
these patients were known to have diabetes before 
transplantation (Table 4). In addition, 4 patients 
are currently receiving oral hypoglycemic agents. 
In patients with renal impairment or hyperglyce-
mia, there was some difference in the dosages of 
tacrolimus and steroids. In this population, the 
tacrolimus dose was usually reduced. No statistical 
significance, however, has been attributed to these 
variations. 
De novo malignanCies. Seven patients developed 
de novo malignancies, 2 of which were skin cancer 
(one basal cell carcinoma and another squamous 
cell carcinoma). Three patients developed lung 
cancer, 1 developed breast cancer, and 1 developed 
glioblastoma of the brain. The lung cancer types 
included one small cell, one oat cell, and one 
adenocarcinoma, which were diagnosed at 84,61, 
and 37 months after LTx at the patient ages of 53, 
49, and 67 years, respectively. These 3 patients had 
a history of smoking; however, 1 patient had 
stopped smoking 12 years before LTx. 
Posttransplantation lymphoproliJerative disorders. Six 
patients developed posttransplantation lymphopro-
!iferative disorders (PTLDs) involving the tonsils 
(2 patients), colon (2 patients), liver (l patient), 
and hepatic hilum (1 patient). One patient with 
colonic PTLD and another with hepatic hilum 
PTLD received three liver transplants and had a 
cytotoxic-positive cross-match with donor lympho-
cytes. Both patients died, 1 of overwhelming cyto-
megalovirus infection, and the other of sepsis, 
respectively. The other 4 patients are currently alive 
and disease free (Table 4). 
Discussion 
Introduction of CsA in the early 1980s led to major 
improvements in patient and graft survival, and the 
incidence and severity of rejection were reduced 
conSiderably. I H+ A more potent immunosuppres-
sive agent. tacrolimus. has contributed to further 
significant reductions in the number of episodes of 
rejection and in the severitv of rejections in liver 
transplant recipients. ri-II Because many patients in 
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randomized trials have been converted from CsA to 
tacrolimus in the event of rejection, it is not 
possible to evaluate the true incidence of improve-
ment in patient and graft survival. However, a 
European multicenter randomized study9 and a 
large series from our center by Todo et ailS have 
shown improved patient and graft survival. The 
initial successes described in these initial trials 
appear to be sustained beyond 7 years of follow-up. 
Rejection rates remain low, and these episodes are 
readily controlled in most instances. The mainte-
nance dose of steroids is also low. and nearly 70% 
of the patients are on mono therapy. Late graft 
losses and/or death are mostly related to a recur-
rence of disease (hepatitis B virus, hepatitiS C virus, 
scleroSing cholangitis) or patient noncompliance. 
In this series, all patients initially received a 
tacrolimus dose three to five times greater than that 
currently used. Long-term chronic nephrotoXicity 
remains a major concern; however. end-stage renal 
disease requiring dialysis or kidney transplantation 
was still less than 4% after 7.5 to 8 years of 
follow-up. The mean serum creatinine levels ob-
served in this series were similar to those reported 
from the US Multicenter Study Group comparing 
CsA with tacrolimus. 16 Hyperkalemia was observed 
in a Significant number of patients and was readily 
controlled with fludrocortisone. Hypertension ap-
peared to be less frequent and less severe clinically 
compared with published data on CSA.16.l7 The 
incidence of new-onset insulin-dependent diabetes 
mellitus was 13% after 7 years in the adult popula-
tion. This adverse event was not observed in 
children. IS Stegall et aP9 reported a 13% incidence 
of new-onset diabetic mellitus when using CsA. 
Knobler et a120 reported that 23% of the patients 
were hyperglycemic after LTx and found no differ-
ence between CsA- and tacrolimus-based immuno-
therapy. De novo malignancy rates were 5.8% in the 
long-term follow-up. One such report on CsA after 
LTx by Levy et al21 reported de novo malignancy 
rates of 4.5%, with a mean follow-up of 35 months. 21 
We have published a similar incidence of 5.7% in 
the larger population taking tacrolimus, which 
compares that risk with the nontransplant popula-
tion matched for age, sex, and length of follow-
Up."2 Six patients (5%) developed PTLD in our 
series, and these patients tended to receive higher 
doses of tacrolimus. The rate of PTLD in the larger 
population taking tacrolimus IS 1.9% for adults and 
11.4% for children, as reported from our center. n 
This rate is similar to that reported using CsA. H 
In conclusion, the benefits of tacrolimus ob-
served in the initial clinical trials are sustained in 
the long term. Approximately 70% of the patients 
can be maintained on mono therapy. Primary graft 
loss caused by either acute or chronic rejection is 
rare under tacrolimus-based immunosuppression. 
The overall toxicity of tacrolimus is not worse than 
that reported with CsA. 
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